Evidence map›Paper›PMID 27176713›Full record

ArticleMolecular medicine reports2016

Diagnostic value of miR-30d-5p and miR-125b-5p in acute myocardial infarction.

Kegang Jia, Ping Shi, Xuejing Han, Tienan Chen, Hongxia Tang, Jing Wang

Abstract read
In one paragraph

Article in Molecular medicine reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Circulating miR-30d Predicts Survival in Patients with Acute Heart Failure.Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology · 2017
    Trial
  4. Article
  5. Article
  6. Article
  7. Expression Analysis ofInternational journal of molecular and cellular medicine · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. MiR-125 Family in Cardiovascular and Cerebrovascular Diseases.Frontiers in cell and developmental biology · 2021
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kegang JiaDepartment of Clinical Laboratory, TEDA International Cardiovascular Hospital, Tianjin 300457, P.R. China.
Ping ShiDepartment of Clinical Laboratory, TEDA International Cardiovascular Hospital, Tianjin 300457, P.R. China.
Xuejing HanDepartment of Clinical Laboratory, TEDA International Cardiovascular Hospital, Tianjin 300457, P.R. China.
Tienan ChenDepartment of Cardiovascular Surgery, TEDA International Cardiovascular Hospital, Tianjin 300457, P.R. China.
Hongxia TangDepartment of Clinical Laboratory, TEDA International Cardiovascular Hospital, Tianjin 300457, P.R. China.
Jing WangDepartment of Clinical Laboratory, TEDA International Cardiovascular Hospital, Tianjin 300457, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rapid and accurate differential diagnosis of acute myocardial infarction (AMI) is crucial for timely interventions and the improvement of prognosis. However, this is difficult to achieve using current methods. Therefore, the present study aimed to evaluate the suitability of circulating microRNAs (miRNAs) as AMI biomarkers in patients with acute coronary syndrome (ACS). miRNA profiling in plasma samples from patients with AMI (n=3) and healthy controls (n=3) was performed using microarrays. Results were then validated in five patients and five healthy controls. miRNA-125b-5p and miR-30d-5p expression levels were quantified in plasma samples from 230 patients with ACS and 79 healthy controls using reverse transcription-quantitative polymerase chain reaction. Routine diagnostic parameters were assessed, including creatinine kinase MB, cardiac troponin I (cTnI) and myoglobin. A total of 33 miRNAs were differentially expressed in patients with AMI and healthy controls. Following validation based on the previously established roles for these miRNAs, six miRNAs were validated. miR‑125b‑5p and miR‑30d‑5p were selected for further investigation. Expression levels of miR‑125b‑5p and miR‑30d‑5p in plasma were higher in patients with ACS compared with the healthy controls (P<0.001). Receiver operating characteristic curve analysis revealed that the area under the curve of miR‑30d‑5p was higher than that of cTnI (0.915 and 0.899). miR‑125b‑5p (sensitivity, 0.808; specificity, 0.845) and miR‑30d‑5p (sensitivity, 0.855; specificity, 0.810) were suitable diagnostic predictors of AMI. Kaplan-Meier survival analysis indicated that miR-125b-5p levels were associated with 6 month cardiovascular events in patients with AMI, but not miR‑30d‑5p. miR-125b-5p and miR-30d-5p presented a diagnostic value for early diagnosis of AMI, and miR‑30d‑5p may have a higher diagnostic value than cTnI.

Indexed as

AdultAgedAged, 80 and overBiomarkersCase-Control StudiesCluster AnalysisComorbidityFemaleGene Expression ProfilingHumansKaplan-Meier EstimateMaleMicroRNAsMiddle AgedMyocardial InfarctionPhenotypeBiomarkersMicroRNAsMIRN125 microRNA, humanMIRN30b microRNA, human

Identifiers

PMID27176713
PMCPMC4918561

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.